Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lasa Supergenerics's enterprise value is ₹461.3 Mil.
Lasa Supergenerics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-282.2 Mil. Therefore, Lasa Supergenerics's EV-to-EBITDA for today is -1.63.
The historical rank and industry rank for Lasa Supergenerics's EV-to-EBITDA or its related term are showing as below:
NSE:LASA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.54 Med: 5.43 Max: 43.39
Current: -1.64
During the past 11 years, the highest EV-to-EBITDA of Lasa Supergenerics was 43.39. The lowest was -23.54. And the median was 5.43.
NSE:LASA's EV-to-EBITDA is ranked worse than 100% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.435
vs NSE:LASA: -1.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lasa Supergenerics's PE Ratio (TTM) for today is calculated as:
Lasa Supergenerics's share price for today is ₹7.19.
Lasa Supergenerics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-4.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Lasa Supergenerics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lasa Supergenerics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lasa Supergenerics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lasa Supergenerics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lasa Supergenerics's EV-to-EBITDA falls into.
Lasa Supergenerics's current Enterprise Value is ₹461.3 Mil.
Lasa Supergenerics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-282.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lasa Supergenerics (NSE:LASA) has a EV-to-EBITDA of -1.63 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lasa Supergenerics. According to the industry distribution chart, Lasa Supergenerics ranks #999999 out of 734 companies in the Drug Manufacturers industry.
Is Lasa Supergenerics' EV-to-EBITDA too high?
Lasa Supergenerics' current EV-to-EBITDA is -1.63. Based on the distribution chart, Lasa Supergenerics ranks #999999 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lasa Supergenerics has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lasa Supergenerics' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lasa Supergenerics ranks #999999 out of 734 companies for EV-to-EBITDA. This places Lasa Supergenerics in the lower half of its industry. The industry median EV-to-EBITDA is 13.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.44, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lasa Supergenerics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lasa Supergenerics's current EV-to-EBITDA is -1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lasa Supergenerics stock overvalued right now?
Based on GuruFocus' analysis, Lasa Supergenerics (NSE:LASA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹4.22, compared to a current price of ₹7.19 — trading 70.4% above its estimated fair value. The current EV-to-EBITDA is -1.63. Lasa Supergenerics' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lasa Supergenerics (NSE:LASA), the current EV-to-EBITDA is -1.63 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lasa Supergenerics (NSE:LASA) Overvalued in 2026?
Based on GuruFocus' analysis, Lasa Supergenerics stock appears to be overvalued.
The current stock price of ₹7.19 is trading 70.4% above its estimated GF Value™ of ₹4.22.
GuruFocus considers Lasa Supergenerics to be Significantly Overvalued.
Key valuation signals for NSE:LASA:
EV-to-EBITDA: -1.63
GF Value™: ₹4.22 vs. price of ₹7.19 (70.4% above fair value)
No single metric tells the full story. See the NSE:LASA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lasa Supergenerics Ltd is engaged in the research, manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and related products. The company specializes in catalyst chemistry and manufactures anthelmintic and veterinary API products. Its product range includes API products, other API products, animal feed ingredients, and reagents for therapeutic use.
43GF Score
Get the complete analysis for NSE:LASA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LASA has been successfully added to your 
